Developing potential cellular and gene therapy products – frequently asked questions (from Catapult’s regulatory round-up for November 2024)
The FDA has issued a draft guidance intended to provide industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy products. Comments are due by 18th February 2025.
Published on the 3rd of december 2024. Read the entire Regulatory Round-up – November 2024 here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (12 février 2025). Developing potential cellular and gene therapy products – frequently asked questions (from Catapult’s regulatory round-up for November 2024). ELSIBI. Consulté le 18 mars 2025 à l’adresse https://doi.org/10.58079/13axo